Design of (225)Ac-PSMA for targeted alpha therapy in prostate cancer.

Kairemo K, Kgatle M, Bruchertseifer F, Morgernstern A, Sathekge MM

DOI: 10.21037/atm-23-1842
Published: 2024 Aug 1
Container: Annals of translational medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21037/atm-23-1842,
  title = {Design of (225)Ac-PSMA for targeted alpha therapy in prostate cancer.},
  author = {Kairemo K and Kgatle M and Bruchertseifer F and Morgernstern A and Sathekge MM},
  year = {2024},
  journal = {Annals of translational medicine},
  doi = {10.21037/atm-23-1842},
  url = {https://doi.org/10.21037/atm-23-1842}
}

RIS

TY  - JOUR
TI  - Design of (225)Ac-PSMA for targeted alpha therapy in prostate cancer.
AU  - Kairemo K
AU  - Kgatle M
AU  - Bruchertseifer F
AU  - Morgernstern A
AU  - Sathekge MM
PY  - 2024
JO  - Annals of translational medicine
DO  - 10.21037/atm-23-1842
UR  - https://doi.org/10.21037/atm-23-1842
ER  -

APA

K, K., M, K., F, B., A, M., & MM, S. (2024). Design of (225)Ac-PSMA for targeted alpha therapy in prostate cancer.. Annals of translational medicine. https://doi.org/10.21037/atm-23-1842

Source records

pubmed · retrieved 2026-09-25T19:13:06.227Z
europe-pmc · retrieved 2026-09-25T19:13:06.211Z